HK1215190A1 - 載體連接型***素類前藥 - Google Patents

載體連接型***素類前藥

Info

Publication number
HK1215190A1
HK1215190A1 HK16103261.8A HK16103261A HK1215190A1 HK 1215190 A1 HK1215190 A1 HK 1215190A1 HK 16103261 A HK16103261 A HK 16103261A HK 1215190 A1 HK1215190 A1 HK 1215190A1
Authority
HK
Hong Kong
Prior art keywords
carrier
linked prostanoid
prodrugs
prostanoid prodrugs
linked
Prior art date
Application number
HK16103261.8A
Other languages
English (en)
Inventor
Harald Rau
Guillaume Maitro
Ulrich Hersel
Oliver Keil
Thomas Wegge
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of HK1215190A1 publication Critical patent/HK1215190A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16103261.8A 2012-12-07 2016-03-21 載體連接型***素類前藥 HK1215190A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196052 2012-12-07
PCT/EP2013/075761 WO2014086961A1 (en) 2012-12-07 2013-12-06 Carrier-linked prostanoid prodrugs

Publications (1)

Publication Number Publication Date
HK1215190A1 true HK1215190A1 (zh) 2016-10-21

Family

ID=47351468

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102161.1A HK1214151A1 (zh) 2012-12-07 2016-02-25 載體連接型***素類前藥
HK16103261.8A HK1215190A1 (zh) 2012-12-07 2016-03-21 載體連接型***素類前藥

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16102161.1A HK1214151A1 (zh) 2012-12-07 2016-02-25 載體連接型***素類前藥

Country Status (8)

Country Link
US (1) US9913912B2 (zh)
EP (1) EP2928501B1 (zh)
JP (1) JP6290243B2 (zh)
CN (1) CN104884093A (zh)
AU (1) AU2013353985B2 (zh)
CA (1) CA2891949C (zh)
HK (2) HK1214151A1 (zh)
WO (1) WO2014086961A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908244C (en) * 2013-03-25 2021-04-20 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US20200276276A1 (en) 2016-03-01 2020-09-03 Ascendis Pharma Bone Diseases A/S PTH Prodrugs
FI3518960T3 (fi) 2016-09-29 2023-10-04 Ascendis Pharma Bone Diseases As Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle
MX2019003182A (es) * 2016-09-29 2019-08-05 Ascendis Pharma Bone Diseases As Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
EP3870285A1 (en) * 2018-10-22 2021-09-01 United Therapeutics Corporation Synthesis of esuberaprost prodrugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03220201A (ja) * 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8252771B2 (en) * 2007-01-31 2012-08-28 Allergan, Inc. Biomaterials and a method for making and using same
PT3050576T (pt) 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
WO2011012715A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US10108630B2 (en) * 2011-04-07 2018-10-23 Microsoft Technology Licensing, Llc Cluster unique identifier
AU2012243434A1 (en) * 2011-04-12 2013-11-28 Commonwealth Scientific And Industrial Research Organisation Polymer conjugated prostaglandin analogues
CN103857413A (zh) 2011-08-12 2014-06-11 阿森迪斯药物股份有限公司 载体连接的曲罗尼尔前药
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
EP2906617B1 (en) 2012-10-11 2018-03-14 Ascendis Pharma A/S Hydrogel prodrugs

Also Published As

Publication number Publication date
HK1214151A1 (zh) 2016-07-22
JP6290243B2 (ja) 2018-03-07
EP2928501B1 (en) 2020-05-06
AU2013353985A1 (en) 2015-05-28
CN104884093A (zh) 2015-09-02
CA2891949C (en) 2021-03-23
US9913912B2 (en) 2018-03-13
WO2014086961A1 (en) 2014-06-12
AU2013353985B2 (en) 2017-07-13
EP2928501A1 (en) 2015-10-14
CA2891949A1 (en) 2014-06-12
JP2016501885A (ja) 2016-01-21
US20150306239A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HK1198359A1 (zh) 載體連接的曲羅尼爾前藥
DK3327112T3 (en) Agse-deficient stamme
EP2934531A4 (en) COMBINATION
EP2754580A4 (en) DUMP TRUCK
DK2830816T3 (en) Hidtil ukendt coatingkoncept
EP2920482A4 (en) BRAKE
HK1204973A1 (zh) 雙氯芬酸製劑
HK1208896A1 (zh) 制動器
EP2935220A4 (en) PERI-carbinol
EP2911673A4 (en) COMBINATION
GB201420527D0 (en) Electrical-wire-protecting member
HK1215190A1 (zh) 載體連接型***素類前藥
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
GB2518076B (en) Electrical-wire-protecting member
EP2920157A4 (en) DI MACRO CYCLEN
EP2873363A4 (en) DIOPSIMETER
EP2834250A4 (de) Lithiumsilikate
EP2925728A4 (en) COMBINATION
GB201207606D0 (en) Prodrugs
EP2908816A4 (en) ASSOCIATION
EP2908815A4 (en) COMBINATION
GB201214607D0 (en) Tidy rebate2
GB201220389D0 (en) Inventor
GB201223358D0 (en) Combines